Disease relevance of Vercyte

• Pipobroman therapy of polycythemia vera [1].
• No hematologic malignancies were seen among patients treated with pipobroman alone; follow-up exceeded 6 yr for 20 patients and the median follow-up period was 3.6 yr [1].
• Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea [2].
• Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman [3].
• The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET [4].

High impact information on Vercyte

• A high proportion of AML and MDS occurring in ET treated with HU (alone or possibly followed by pipobroman) have morphologic, cytogenetic, and molecular characteristics of the 17p- syndrome [5].
• Bone marrow aplasia after pipobroman: an immune-mediated mechanism [6]?
• Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset [7].
• At the present time, but in only a few cases with long-term following, no myelo-fibrosis with splenic metaplasia has been observed in the pipobroman-treated cases [8].
• Overall, 98.3% of patients initially responded to pipobroman, with very mild toxicity [9].

Associations of Vercyte with other chemical compounds

• Because of the lack of Phase III trials, it is not clear which of the cytoreductive drugs - hydroxyurea, pipobroman, IFN-alpha, pegylated-IFNs or anagrelide - is the best therapeutic option [10].

Analytical, diagnostic and therapeutic context of Vercyte

• In the adult group, single-agent chemotherapy was performed with good remission using pipobroman or interferon [11].
• We performed a retrospective study to assess the incidence of AL in ET patients treated with pipobroman (PB) as first-line therapy [12].

References